Novartis
NEWS
From CRISPR to spider silk there are some great scientific research stories out this week.
Novartis has walked into the European Congress of Rheumatology to make a case for two of its drugs, Cosentyx and canakinumab.
Now, two studies published in Nature Medicine suggest that CRISPR may lead to cancer unintentionally.
Regenxbio snagged $100 million from Novartis under its license agreement with gene-therapy company AveXis, which the Swiss company acquired for $8.7 billion earlier this year.
The Bill and Melinda Gates Foundation has spun off a biotech company called The Bill & Melinda Gates Medical Research Institute (MRI) located in Boston. Although it found its temporary space in Cambridge, Massachusetts in January, it “officially” launched Thursday at the BIO International Convention in Boston.
One of the hot topics at this year’s BIO International Convention being held in Boston is “patient-centricity.”
The 2018 BIO International Convention will be officially running from June 4 through June 7 and is celebrating 25 years of innovation.
Since 2009 May 30 has been set aside as a day to raise awareness and campaign for an end to multiple sclerosis. The theme this year is focused on the research being conducted to develop a cure for the neurological disease.
Within the next six years, the multiple myeloma market is projected to be $37.5 billion – an incredible growth of $30 billion since 2015, when the market was valued at about $7.5 billion.
JOBS
IN THE PRESS